002262 恩华药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)9.00613.77016.65217.20217.088
总资产报酬率 ROA (%)7.89711.97214.50515.01814.792
投入资产回报率 ROIC (%)8.56313.04015.92316.69616.598

边际利润分析
销售毛利率 (%)73.86372.12773.55872.82976.260
营业利润率 (%)26.50420.28623.45823.45223.344
息税前利润/营业总收入 (%)26.10619.55822.45822.79822.546
净利润/营业总收入 (%)23.00317.84620.02220.51520.474

收益指标分析
经营活动净收益/利润总额(%)100.90497.40599.77496.64994.928
价值变动净收益/利润总额(%)4.2465.2145.0574.3683.664
营业外收支净额/利润总额(%)-0.844-2.224-3.076-1.172-1.370

偿债能力分析
流动比率 (X)6.2185.9175.6836.4555.857
速动比率 (X)5.4265.2245.0635.6834.955
资产负债率 (%)12.29712.96013.82112.52813.847
带息债务/全部投入资本 (%)3.6314.0034.0961.6490.850
股东权益/带息债务 (%)2,626.2112,367.9712,309.8425,869.33511,456.128
股东权益/负债合计 (%)715.651674.048625.837700.820626.404
利息保障倍数 (X)-148.744-68.043-74.711-59.674-46.628

营运能力分析
应收账款周转天数 (天)90.28590.19879.76966.25162.707
存货周转天数 (天)172.794154.934154.132176.733232.955